Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ariad Pharmaceuticals (ARIA) Share Price

Media coverage about Ariad Pharmaceuticals (NASDAQ:ARIA) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ariad Pharmaceuticals earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave media coverage about the pharmaceutical company an impact score of 45.3472842725256 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) remained flat at $$23.99 during trading on Friday. The company has a debt-to-equity ratio of -11.28, a quick ratio of 3.15 and a current ratio of 3.17.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-ariad-pharmaceuticals-aria-share-price.html.

Ariad Pharmaceuticals Company Profile

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Insider Buying and Selling by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit